State-by-state data on United States COVID-19 vaccinations data

Acknowledgement and License

All data are produced by Our World in Data are completely open access under the Creative Commons BY license. You have the permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited. In the case of our vaccination dataset, please give the following citation:

Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021). https://doi.org/10.1038/s41562-021-01122-8

Data Set Column Details

location : name of the state or federal entity. date: date of the observation. total vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. total vaccinations per hundred: total vaccinations per 100 people in the total population of the state. daily vaccinations raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily vaccinations instead. daily vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. daily vaccinations per million: daily vaccinations per 1,000,000 people in the total population of the state. people vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. people vaccinated per hundred: people vaccinated per 100 people in the total population of the state. people fully vaccinated: total number of people who received all doses prescribed by the initial vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. people fully vaccinated per hundred: people fully vaccinated per 100 people in the total population of the state. total distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System. total distributed per hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state. share doses used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System. total boosters: total number of COVID-19 vaccination booster doses administered (doses administered beyond the number prescribed by the initial vaccination protocol) total boosters per hundred: total boosters per 100 people in the total population.

Time Span

20th Dec 2020 to 28th Dec 2022

On May 21, 2023, Egypt administered 14,954 doses of the vaccine against the coronavirus (COVID-19). The country received its first shipment of Sinopharm vaccines in December as the first country in the African continent to receive any doses. The health minister declared the start of the vaccination program on January 24, 2021, and was set to start with medical staff as part of phase three clinical trials of the vaccine developed in China.

On January 25, 2021, 219 jabs of the vaccine developed by Sinopharm were administered. The number of daily administered doses started to increase from January 31, 2021, reaching its highest daily count on November 13, 2021. Moreover, 854,000 AstraZeneca/Oxford vaccines were secured in late March 2021 via the COVAX initiative. Egypt domestically produces the Sinovac vaccine in Egypt in its state-owned vaccine production company and plans to further increase its production to become a hub for producing vaccines.

India administered over 2.2 billion vaccine doses for the coronavirus (COVID-19) as of October 20, 2022. The number of people infected with the virus was declining across the Asian country. With the onset of the second wave since late March 2021, the central government increased funding to boost vaccination production.

Please see FAQ for latest information on COVID-19 Data Hub Data Flows. https://covid-19.geohive.ie/pages/helpfaqs Field label Field Name Explanation

ExtractDate Extract Date Date the data is Extracted

Latitude Latitude

Longitude Longitude

VaccinationDate Vaccination Date Date the Vaccination occurred

Dose1 Dose 1

Dose2 Dose 2

SingleDose Single Dose

Dose1Cum Dose 1 Cumulative

Dose2Cum Dose 2 Cumulative

SingleDoseCum Single Dose Cumulative

PartiallyVacc At Least One Dose This is Dose 1 Cumulative + Single Dose Cumulative

FullyVacc Fully Vaccinated This is Dose 2 Culmulative + Single Dose Cumulative

PopOver12 Population Over 12 Population Over 12 using CSO Population estimates 2021

PartialPercent % At Least One Dose of Pop. over age 12 Formula: At Least One Dose/ Population Over 12

FullyPercent % Fully vaccinated of Pop. over age 12 Formula: Fully Vaccinated/ Population Over 12

Demographic factors reported at baseline and drug levels detected at baseline and week 6.

Please see FAQ for latest information on COVID-19 Data Hub Data Flows https://covid-19.geohive.ie/pages/helpfaqs

Read the associated blogpost for a detailed description of how this dataset was prepared; plus extra code for producing animated maps.

Context

The 2019 Novel Coronavirus (COVID-19) continues to spread in countries around the world. This dataset provides daily updated number of reported cases & deaths in Germany on the federal state (Bundesland) and county (Landkreis/Stadtkreis) level. In April 2021 I added a dataset on vaccination progress. In addition, I provide geospatial shape files and general state-level population demographics to aid the analysis.

Content

The dataset consists of thre main csv files: covid_de.csv, demgraphics_de.csv, and covid_de_vaccines.csv. The geospatial shapes are included in the de_state.* files. See the column descriptions below for more detailed information.

• covid_de.csv: COVID-19 cases and deaths which will be updated daily. The original data are being collected by Germany's Robert Koch Institute and can be download through the National Platform for Geographic Data (the latter site also hosts an interactive dashboard). I reshaped and translated the data (using R tidyverse tools) to make it better accessible. This blogpost explains how I prepared the data, and describes how to produces animated maps.

• demographics_de.csv: General Demographic Data about Germany on the federal state level. Those have been downloaded from Germany's Federal Office for Statistics (Statistisches Bundesamt) through their Open Data platform GENESIS. The data reflect the (most recent available) estimates on 2018-12-31. You can find the corresponding table here.

• covid_de_vaccines.csv: In April 2021 I added this file that contains the Covid-19 vaccination progress for Germany as a whole. It details daily doses, broken down cumulatively by manufacturer, as well as the cumulative number of people having received their first and full vaccination. The earliest data are from 2020-12-27.

• de_state.*: Geospatial shape files for Germany's 16 federal states. Downloaded via Germany's Federal Agency for Cartography and Geodesy . Specifically, the shape file was obtained from this link.

Column Description

COVID-19 dataset covid_de.csv:

• state: Name of the German federal state. Germany has 16 federal states. I removed converted special characters from the original data.

• county: The name of the German Landkreis (LK) or Stadtkreis (SK), which correspond roughly to US counties.

• age_group: The COVID-19 data is being reported for 6 age groups: 0-4, 5-14, 15-34, 35-59, 60-79, and above 80 years old. As a shortcut the last category I'm using "80-99", but there might well be persons above 99 years old in this dataset. This column has a few NA entries.

• gender: Reported as male (M) or female (F). This column has a few NA entries.

• date: The calendar date of when a case or death were reported. There might be delays that will be corrected by retroactively assigning cases to earlier dates.

• cases: COVID-19 cases that have been confirmed through laboratory work. This and the following 2 columns are counts per day, not cumulative counts.

• deaths: COVID-19 related deaths.

• recovered: Recovered cases.

Demographic dataset demographics_de.csv:

• state, gender, age_group: same as above. The demographic data is available in higher age resolution, but I have binned it here to match the corresponding age groups in the covid_de.csv file.

• population: Population counts for the respective categories. These numbers reflect the (most recent available) estimates on 2018-12-31.

Vaccination progress dataset covid_de_vaccines.csv:

• date: calendar date of vaccination

• doses, doses_first, doses_second: Daily count of administered doses: total, 1st shot, 2nd shot.

• pfizer_cumul, moderna_cumul, astrazeneca_cumul: Daily cumulative number of administered vaccinations by manufacturer.

• persons_first_cumul, persons_full_cumul: Daily cumulative number of people having received their 1st shot and full vaccination, respectively.

Acknowledgements

All the data have been extracted from open data sources which are being gratefully acknowledged:

• The [Robert ...

Context

• First case of COVID-19 in India was announced on 27th January 2020 in Thrissur Kerala. After October 2020, there was some relief due to the subsiding of the curve of the covid case.
• In January 2020, the Government of India approved two vaccines i.e. Astra-Zeneca's Vaccine produced by Serum Institute - Covidsheild and Bharat Biotech's indigenous vaccine - Covaxin.
• This dataset deals with these vaccinations in India and provides insights into them. The two files provide information about daily COVID-19 vaccinations throughout the country and total vaccinations in each state.
• The data was collected from Our World in Data Github repo for covid-19 and Government of India website containing Vaccinations State Data, merged with relevant attributes, and uploaded.
• Government of India also approved Russia's Sputnik V for emergency use authorization on 12th April 2021.

Content

Covid-19_India_Daywise_Vaccinations.csv

Columns: - location- Location of the vaccination(country). - date- Date in format dd-mm-yyyy. - vaccine- Name of the vaccine(s) administered in the country on that day. - source_url- Source of the information for the vaccination. - total-vaccinations- Total number of doses administered till that day. If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. - total_vaccinations_per_hundred- total_vaccinations per 100 people in the total population. - people_vaccinated- Total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. - people_vaccinated_per_hundred- people_vaccinated per 100 people in the total population. - people_fully_vaccinated- Total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. - people_fully_vaccinated_per_hundred- people_fully_vaccinated per 100 people in the total population. - daily_vaccinations- New doses administered per day. - daily_vaccinations_per_million- daily_vaccinations per 1,000,000 people in the total population. - daily_change_in_vaccinations- Change in the number of doses administered (daily_vaccinations) from the previous day.

Covid-19_Statewise_Vaccination_India.csv

Columns: - State/Union Territory- Name of the State or Union Territory. - Population (2011 census)- Population of the State/UT based on 2011 census. - 1st dose- Number of first doses that were administered. - 2nd dose- Number of second doses that were administered. - Cumulative doses administered- Total number of doses administered till date. - Percentage of people given atleast one dose- Percent of the population of the state. - Percentage of people fully vaccinated- Percent of the population of the state.

Acknowledgements

I like to specify that I am only making available to Kagglers the data that is produced and maintained by Our World in Data through their Github repo, and also the Ministry of Health and Family Welfare Government of India which provide daily vaccine stats through their website. - Our World in Data Github Repo - Ministry of Health and Family Welfare Government of India

Inspiration

From this data, what you could do is: - Visualisations about the daily vaccination trends in the country. - Which state has the fastest pace in vaccination? - Prediction of future daily vaccinations in the country.

As of March 20, 2023, over 13 billion COVID-19 vaccine doses had been administered worldwide, with the United States accounting for almost 672 million of this total. This statistic shows the number of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Dataset of COVID-19 HSE Weekly Vaccination data. Time series available from Week 53 2020 to Week 18 2024. CategoryField labelField NameExplanation ExtractDateExtract DateDate the data is Extracted LatitudeLatitude LongitudeLongitude VaccinationDateVaccination DateDate the Vaccination occurred WeekWeekDetails of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/ TotalDailyVaccinesTotal Daily Vaccines GenderMale Female NA Dose NumberDose1Dose 1 Dose2Dose 2 SingleDoseSingle Dose Vaccine BrandModerna Pfizer Janssen AstraZeneca Age GroupPartial_Age0to9At Least One Dose Age 0 to 11Dose 1 of Astrazenenca, MRNA or Single Dose VaccinePartial_Age10to19At Least One Dose Age 12 to 19Partial_Age20to29At Least One Dose Age 20 to 29Partial_Age30to39At Least One Dose Age 30 to 39Partial_Age40to49At Least One Dose Age 40 to 49Partial_Age50to59At Least One Dose Age 50 to 59Partial_Age60to69At Least One Dose Age 60 to 69Partial_Age70to79At Least One Dose Age 70 to 79Partial_Age80+At Least One Dose Age80+Partial_NAAt Least One Dose Not AssignedAge Group CumulativeParCum_Age0to9Cumulative Age 0 to 11Cumulative At least One Dose Age 0 to 11ParCum_Age10to19Cumulative Age 12 to 19Cumulative At least One Dose Age 12 to 19ParCum_Age20to29Cumulative Age 20 to 29Cumulative At least One Dose Age 20 to 29ParCum_Age30to39Cumulative Age 30 to 39Cumulative At least One Dose Age 30 to 39ParCum_Age40to49Cumulative Age 40 to 49Cumulative At least One Dose Age 40 to 49ParCum_Age50to59Cumulative Age50 to 59Cumulative At least One Dose Age 50 to 59ParCum_Age60to69Cumulative Age 60 to 69Cumulative At least One Dose Age 60 to 69ParCum_Age70to79Cumulative Age 70 to 79Cumulative At least One Dose Age 70 to 79ParCum_80+Cumulative Age 80+Cumulative At least One Dose Age 80+Age Group Cumulative PercentParCum_NACumulative Age Not AssignedCumulative At least One Dose Age Not AssignedParPer_Age0to9At Least One Dose Percent Age 0 to 11Cumulative At least One Dose Age cohort/ Age cohort populationParPer_Age10to19At Least One Dose Percent Age 12 to 19ParPer_Age20to29At Least One Dose Percent Age 20 to 29ParPer_Age30to39At Least One Dose Percent Age 30 to 39ParPer_Age40to49At Least One Dose Percent Age 40 to 49ParPer_Age50to59At Least One Dose Percent Age 50 to 59ParPer_Age60to69At Least One Dose Percent Age 60 to 69ParPer_Age70to79At Least One Dose Percent Age 70 to 79ParPer_80+At Least One Dose Percent 80+ParPer_NAAt Least One Dose Percent Not AssignedAge GroupFully_Age0to9Fully vaccinated Age 0 to 11Dose 2 of An MRNA or AztraZeneca Vaccine or a single dose vaccine of a JanssenFully_Age10to19Fully vaccinated Age 12 to 19Fully_Age20to29Fully vaccinated Age 20 to 29Fully_Age30to39Fully vaccinated Age 30 to 39Fully_Age40to49Fully vaccinated Age 40 to 49Fully_Age50to59Fully vaccinated Age 50 to 59Fully_Age60to69Fully vaccinated Age 60 to 69Fully_Age70to79Fully vaccinated Age 70 to 79Fully_Age80+Fully vaccinated Age 80+Fully_NAFully vaccinated Age Not Available Age Group CumulativeFullyCum_Age0to9Cumulative Fully vaccinated Age 0 to 11 FullyCum_Age10to19Cumulative Fully vaccinated Age 12 to 19 FullyCum_Age20to29Cumulative Fully vaccinated Age 20 to 29 FullyCum_Age30to39Cumulative Fully vaccinated Age 30 to 39 FullyCum_Age40to49Cumulative Fully vaccinated Age 40 to 49 FullyCum_Age50to59Cumulative Fully vaccinated Age 50 to 59 FullyCum_Age60to69Cumulative Fully vaccinated Age 60 to 69 FullyCum_Age70to79Cumulative Fully vaccinated Age 70 to 79 FullyCum_80+Cumulative Fully vaccinated Age 80+ Age Group Cumulative PercentFullyCum_NACumulative Fully vaccinated Age Not Available FullyPer_Age0to9Cumulative Percent Fully vaccinated Age 0 to 11Cumulative Fully Vaccinated Age cohort/ Age cohort populationFullyPer_Age10to19Cumulative Percent Fully vaccinated Age 12 to 19FullyPer_Age20to29Cumulative Percent Fully vaccinated Age 20 to 29FullyPer_Age30to39Cumulative Percent Fully vaccinated Age 30 to 39FullyPer_Age40to49Cumulative Percent Fully vaccinated Age 40 to 49FullyPer_Age50to59Cumulative Percent Fully vaccinated Age 50 to 59FullyPer_Age60to69Cumulative Percent Fully vaccinated Age 60 to 69FullyPer_Age70to79Cumulative Percent Fully vaccinated Age 70 to 79FullyPer_80+Cumulative Percent Fully vaccinated Age 80+FullyPer_NACumulative Percent Fully vaccinated Age Not Available

With the federal COVID-19 Public Health Emergency ending on May 11th, the Montana Department of Health & Human Services will discontinue weekly updates to the COVID-19 case tracking and vaccine map dashboards and feature services. The last weekly update to the dashboards will take place on May 5th, 2023. After this final data update, the dashboards will remain available to viewers until July 14th, 2023. However, it should be noted that data will not be current after May 5th, 2023.To access up-to-date COVID-19 data for Montana after 5/11/2023, visit the CDC’s COVID Data Tracker website: https://covid.cdc.gov/covid-data-trackerThe Montana COVID-19 Case and Test Data web service hosts COVID-19 statistics for the state of Montana by county. The data is derived from local health officials at the county level who report cases to the Montana Department of Health and Human Services. DPHHS tabulates case data and then gives the data to the Montana State Library to publish through this web service. The daily updates are managed by the Disaster and Emergency Service State Emergency Coordination Center. The feature service is comprised of Montana's county geography with attributes that summarize Total COVID-19 cases by age (10-year groups), by sex (M/F/U), new cases, total deaths, hospitalization count, total recovered and the number of total active cases. The two tables store various stats that include the total number of tests completed, and the number of new tests completed for individual test dates; and individual case data which includes age group, sex, county or residence and recovery status. Montana public health agencies and the Governor's Coronavirus task Force are actively working to limit the spread of novel coronavirus in Montana. The Montana State Library is aiding this effort by geo-enabling public health information and emergency response data to help decision-makers, State Emergency Coordination Center and the Governor's Coronavirus Task Force understand the spread of the disease.

On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased its collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit: U.S. Centers for Disease Control and Prevention (CDC)For more information, visit the Johns Hopkins Coronavirus Resource Center.This map is updated weekly and currently shows data through March 5, 2023, which will be the final update of this map.Note: Nebraska stopped reporting county level-results on 5/25/2021 and re-started on 9/26/21 with a lump-sum representing the previous four months - this impacted the weekly sum of cases fields.It shows COVID-19 Trend for the most recent Monday with a colored dot for each county. The larger the dot, the longer the county has had this trend. Includes Puerto Rico, Guam, Northern Marianas, U.S. Virgin Islands.The intent of this map is to give more context than just the current day of new data because daily data for COVID-19 cases is volatile and can be unreliable on the day it is first reported. Weekly summaries in the counts of new cases smooth out this volatility. Click or tap on a county to see a history of trend changes and a weekly graph of new cases going back to February 8, 2020. This map is updated every Monday* based on data through the previous Sunday. See also this version of the map for another perspective.COVID-19 Trends show how each county is doing and are updated daily. We base the trend assignment on the number of new cases in the past two weeks and the number of active cases per 100,000 people. To learn the details for how trends are assigned, see the full methodology. There are five trends:Emergent - New cases for the first time or in counties that have had zero new cases for 60 or more days.Spreading - Low to moderate rates of new cases each day. Likely controlled by local policies and individuals taking measures such as wearing masks and curtailing unnecessary activities.Epidemic - Accelerating and uncontrolled rates of new cases.Controlled - Very low rates of new cases.End Stage - One or fewer new cases every 5 days in larger populations and fewer in rural areas.*Starting 8/22/2021 we began updating on Mondays instead of Tuesdays as a result of optimizing the scripts that produce the weekly analysis. For more information about COVID-19 trends, see the full methodology. Data Source: Johns Hopkins University CSSE US Cases by County dashboard and USAFacts for Utah County level Data.

Indonesia MoH: COVID-19: To-Date: Vaccination: Step 2 data was reported at 174,982,453.000 Person in 05 Feb 2025. This stayed constant from the previous number of 174,982,453.000 Person for 31 Dec 2024. Indonesia MoH: COVID-19: To-Date: Vaccination: Step 2 data is updated daily, averaging 174,817,140.500 Person from Jan 2021 (Median) to 05 Feb 2025, with 1424 observations. The data reached an all-time high of 175,385,832.000 Person in 16 Mar 2023 and a record low of 20,810.000 Person in 30 Jan 2021. Indonesia MoH: COVID-19: To-Date: Vaccination: Step 2 data remains active status in CEIC and is reported by Ministry of Health. The data is categorized under High Frequency Database’s Disease Outbreaks – Table ID.HLB001: Coronavirus Disease 2019 (Covid-19): Number of Vaccination. First Stage and Second Stage refers to vaccine injection stage given to the people. Indonesia uses SINOVAC produced vaccine which entitled injection being done twice for optimum effect.

On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased its collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit: U.S. Centers for Disease Control and Prevention (CDC)For more information, visit the Johns Hopkins Coronavirus Resource Center.Trends represent the day-to-day rate of new cases with a focus on the most recent 10 to 14 days. Includes Puerto Rico, Guam, Northern Marianas, and U.S. Virgin Islands. Daily new case counts are volatile for many reasons and sometimes the trends reflect that volatility. Thus, we decided to include longer-term summaries here. County Trends as of 9 Mar 20230 (-0) in Emergent1135 (+51) in Spreading1664 (-63) in Epidemic230 (+10) in Controlled110 (+2) in End StageNotes: Many states now only report once per week, and FL only once every two weeks. On 3/7/2022 we adjusted the formula for active cases to reflect the Omicron Variant which is documented to cause lower rates of serious and severe illness. To produce these trends we analyze daily updates from the Johns Hopkins University Coronavirus COVID-19 Global Cases Dashboard, though we expect to be one day behind the dashboard’s live feeds to allow for quality assurance of the data.For more information about COVID-19 trends, see our country level trends story map and the full methodology.Data Source: Johns Hopkins University CSSE US Cases by County dashboard and USAFacts for Utah County level Data.Feature layer generated from running the Join Features solution that is the basis for daily updates for the U.S. County COVID-19 Tends Story Map.

Context

Yesterday, hopes soared that an end to the pandemic may finally be in sight after an interim analysis showed Pfizer/BioNTech's vaccine candidate provided 90 percent protection in trials. It performed much better than experts had hoped for and manufacturing has already started with Pfizer stating it hopes to supply 50 million doses in 2020 and 1.3 billion doses in 2021. Pfizer chairman and chief executive Albert Bourla said that “Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” adding that “we are reaching this critical milestone in our vaccine development programme at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

The rush to develop a Covid-19 vaccine has gained traction in recent months and a representative from the Russian health ministry also claimed the country's Sputnik V is up to 90 percent effective. Great hopes have also been pinned on a coronavirus vaccine candidate being developed by the University of Oxford that successfully triggered a strong immune response in trials involving 1,077 people. Scientific journal The Lancet had published hugely promising results of Phase I/II trials in July for the University of Oxford vaccine and it provoked a T cell response within 14 days of vaccination and an antibody response within 28 days.

https://www.statista.com/chart/22325/number-of-covid-19-vaccine-candidates/

Content

Vaccines generally take years to develop but candidates are now being developed at an unprecedented pace. Nearly 200 Covid-19 vaccine candidates are now listed by the World Health Organization, according to The Guardian and several are already in advanced testing. The data shows that the bulk of candidates are in the pre-clinical stage of testing where the vaccine is given to animals to see if it triggers an immune response. 39 are in phase I trials where it is administered to a small group of people to determine whether it is safe. 18 are in phase II where the candidate is given to hundreds of people to evaluate further safety issues as well as dosage. The last stage is Phase III, of which 11 candidates are currently in, and it involves thousands of people receiving the vaccine to eliminate any final safety fears, particularly considering side effects.

Acknowledgements

Niall McCarthy, Data Journalist. https://www.statista.com/chart/22325/number-of-covid-19-vaccine-candidates/

Inspiration

Covid-19

Background: Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It's being developed by public sector manufacturers in Thailand, Vietnam, and Brazil; herein are initial results from Thailand. Methods: This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy males and non-pregnant females, aged 18-59 years and negative for SARS-CoV-2 antibodies, were eligible. Participants were randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 µg, 1 µg+CpG1018 (a toll-like receptor 9 agonist), 3 µg, 3 µg+CpG1018, 10 µg, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov (NCT04764422). Findings: Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enroled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia (<32%). The proportion reporting a vaccine-related AE ranged from 5·7% to 17·1% among vaccine groups and was 2·9% in controls; there was no vaccine-related serious adverse event. The 10 µg formulation's immunogenicity ranked best, followed by 3 µg+CpG1018, 3 µg, 1 µg+CpG1018, and 1 µg formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122·23 international units per mL (IU/mL; 1 µg, 95% confidence interval (CI) 86·40-172·91) to 474·35 IU/mL (10 µg, 95% CI 320·90-701·19), with 93·9% to 100% of vaccine groups attaining a ≥ 4-fold increase over baseline. Interpretation: NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 µg and 3 µg+CpG1018 formulations advanced to phase 2

COVID-19 Reopening Data from Associated Press and Kantar Media

Access regularly updated data from The Associated Press and Kantar Media containing information on events at the global, national and state levels as economies reopen following the coronavirus pandemic via AP Planner.

AP Planner is a paid service from The Associated Press & Kantar Media.

The four data files below feature the following event types:

• Environmental, Social and Governance (ESG): Events related the factors that measure the sustainability and societal impact of an investment in a company or business.
• Healthcare, Pharmaceuticals and Bio Tech: Health care providers and services, health care equipment and supplies, and health care technology companies. Drug and vaccine production, as well as biological substances for the purposes of drug discovery and diagnostic development.
• Politics: U.S. political news and events.
• Diversity and Discrimination: News and events related to race, religion, gender, sexuality, disability and age.

All data is compiled by a dedicated staff with over 15 years of forward planning research experience, employing data verification and processes designed to provide reliable and up-to-date information.

The data can be used to help:

• Provide signals to investors on how to act and at what speed based on the types of events returning across industries.
• Analyze risk associated with companies based on when they're reopening.
• Retain your own customer base based on reopening dates for vendors and competitors.
• Track COVID regulations to prepare inventory and guest policies.

The following data files are samples - if you are interested in licensing the full, regularly updated database, please contact Opal Barclay (obarclay@ap.org) at The Associated Press or Click on Request Access Button above.

​

***

FAQs

Why does AP and Kantar compile this data?_ The data is sourced from AP Planner, a product offered by The Associated Press and Kantar Media. AP Planner is a searchable database of future events that is updated daily and intended for research, not publication.

What information does AP Planner contain?_ AP Planner is global in scope and contains more than 100,000 U.S. and international events from the world of news, current affairs, politics, business, lifestyle and more - all searchable up to 12 months ahead.

Where does the information come from?_ AP Planner aggregates listings from tens of thousands of organizations worldwide. Our research staff monitors over 350,000 websites and uses a verity of secondary sources including press releases, corporate announcements and other outlets to ensure accuracy.

How can I be confident of the data's quality and accuracy?_ We have a dedicated research staff with over 15 years of forward planning research experience. They employ data verification and updating processes designed to provide our customers with completely reliable and up-to-date information.

Can I export data into other applications?_ Yes, AP Planner data can be exported as an Excel file or an Outlook calendar file. The data is also accessible via API.

Who can I contact to learn more about AP Planner?_ Opal Barclay, obarclay@ap.org.

India reported almost 45 million cases of the coronavirus (COVID-19) as of October 20, 2023, with more than 44 million recoveries and about 532 thousand fatalities. The number of cases in the country had a decreasing trend in the past months.

Burden on the healthcare system

With the world's second largest population in addition to an even worse second wave of the coronavirus pandemic seems to be crushing an already inadequate healthcare system. Despite vast numbers being vaccinated, a new variant seemed to be affecting younger age groups this time around. The lack of ICU beds, black market sales of oxygen cylinders and drugs needed to treat COVID-19, as well as overworked crematoriums resorting to mass burials added to the woes of the country. Foreign aid was promised from various countries including the United States, France, Germany and the United Kingdom. Additionally, funding from the central government was expected to boost vaccine production.

Situation overview
Even though days in April 2021 saw record-breaking numbers compared to any other country worldwide, a nation-wide lockdown has not been implemented. The largest religious gathering - the Kumbh Mela, sacred to the Hindus, along with election rallies in certain states continue to be held. Some states and union territories including Maharashtra, Delhi, and Karnataka had issued curfews and lockdowns to try to curb the spread of infections.

Content

The WHO coronavirus (COVID-19) dashboard presents official daily counts of COVID-19 cases, deaths and vaccine utilization reported by countries, territories and areas. Through this dashboard, we aim to provide a frequently updated data visualization, data dissemination and data exploration resource, while linking users to other useful and informative resources.

Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, vaccination strategy, and reporting strategies.

Acknowledgements

© World Health Organization 2020, All rights reserved.

WHO supports open access to the published output of its activities as a fundamental part of its mission and a public benefit to be encouraged wherever possible. Permission from WHO is not required for the use of the WHO coronavirus disease (COVID-19) dashboard material or data available for download. It is important to note that:

WHO publications cannot be used to promote or endorse products, services or any specific organization.

WHO logo cannot be used without written authorization from WHO.

WHO provides no warranty of any kind, either expressed or implied. In no event shall WHO be liable for damages arising from the use of WHO publications.

For further information, please visit WHO Copyright, Licencing and Permissions.

Citation: WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: https://covid19.who.int/

Inspiration

Daily cases start increasing suddenly just before the new year and there's a fear for the upcoming wave. Everybody starts to predict the peak cases in the 3rd wave and the date the peak will be reached. Assume you are in the 1st week of January 2022 and there's panic in the country, for the Omicron variant is said to be highly transmittable. Using your machine learning and deep learning skills, you have to create a model that predicts accurately the peak for the 3rd wave.